Literature DB >> 15359012

Huntingtin and its role in neuronal degeneration.

Shi-Hua Li1, Xiao-Jiang Li.   

Abstract

Huntington's disease results from a polyglutamine expansion in the N-terminal region of huntingtin (htt). This abnormality causes protein aggregation and leads to neurotoxicity. Despite its widespread expression in the brain and body, mutant htt causes selective neurodegeneration in Huntington's disease patient brains. However, Huntington's disease mouse models expressing mutant htt do not have obvious neurodegeneration despite significant neurological symptoms. Most Huntington's disease mouse models display the accumulation of toxic N-terminal mutant htt fragments in both the nucleus and neuronal processes, suggesting that these subcellular sites are hotspots for the early neuropathology of Huntington's disease. Intranuclear htt affects gene expression and may cause neuronal dysfunction. Mutant htt in neuronal processes affects axonal transport and induces degeneration, and these effects may be more relevant to the selective neurodegeneration in Huntington's disease. Growing evidence has also suggested that mutant htt mediates multiple pathological pathways. This review discusses the early pathological changes identified in Huntington's disease cellular and animal models. These changes may be the causes of neurode-generation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15359012     DOI: 10.1177/1073858404266777

Source DB:  PubMed          Journal:  Neuroscientist        ISSN: 1073-8584            Impact factor:   7.519


  40 in total

1.  Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.

Authors:  Kuan-Yu Liu; Yu-Chiau Shyu; Brett A Barbaro; Yuan-Ta Lin; Yijuang Chern; Leslie Michels Thompson; Che-Kun James Shen; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-11-14       Impact factor: 6.150

2.  Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells.

Authors:  Ferdinando Squitieri; Vittorio Maglione; Sara Orobello; Francesco Fornai
Journal:  J Neural Transm (Vienna)       Date:  2011-04-26       Impact factor: 3.575

Review 3.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

4.  Raft-like microdomains play a key role in mitochondrial impairment in lymphoid cells from patients with Huntington's disease.

Authors:  Laura Ciarlo; Valeria Manganelli; Paola Matarrese; Tina Garofalo; Antonella Tinari; Lucrezia Gambardella; Matteo Marconi; Maria Grasso; Roberta Misasi; Maurizio Sorice; Walter Malorni
Journal:  J Lipid Res       Date:  2012-07-06       Impact factor: 5.922

Review 5.  Adult neurogenesis in neurodegenerative diseases.

Authors:  Beate Winner; Jürgen Winkler
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-01       Impact factor: 10.005

Review 6.  Huntington's Disease and Mitochondria.

Authors:  Mohammad Jodeiri Farshbaf; Kamran Ghaedi
Journal:  Neurotox Res       Date:  2017-06-21       Impact factor: 3.911

Review 7.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

8.  Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies.

Authors:  Jeffrey N Savas; Anthony Makusky; Søren Ottosen; David Baillat; Florian Then; Dimitri Krainc; Ramin Shiekhattar; Sanford P Markey; Naoko Tanese
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-31       Impact factor: 11.205

9.  Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis.

Authors:  Guohao Wang; Xudong Liu; Marta A Gaertig; Shihua Li; Xiao-Jiang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-07       Impact factor: 11.205

Review 10.  Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Authors:  Robert D Wyse; Gary L Dunbar; Julien Rossignol
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.